Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 3
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
EGFR exon 19 deletion
gastric cancer · Immune Checkpoint Inhibitor
EGFR exon 19 deletion is flagged as trial selection rising because public trials show inclusion required evidence in 3 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 1
Common snippets: MSI-H
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07432295 | https://clinicaltrials.gov/study/NCT03894618 | https://clinicaltrials.gov/study/NCT07270991